Lula Sherri Mitchell
Medical · Riverdale, GANPI 1710082458
Payments from drug & device makers
Across 101 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$533
- Abbott$370
- Novo Nordisk$362
- AbbVie$179
- Sanofi-aventis U.S. LLC$175
- Otsuka America Pharmaceutical, Inc.$127
- plus $504 from 15 others
What the payments were for
- Food & beverage$2,19097%
- Other$603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $533 |
| Abbott | 8 | $370 |
| Novo Nordisk | 24 | $362 |
| AbbVie | 11 | $179 |
| Sanofi-aventis U.S. LLC | 9 | $175 |
| Otsuka America Pharmaceutical, Inc. | 1 | $127 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Boehringer Ingelheim | 5 | $105 |
| Welch Allyn | 1 | $60 |
| Dexcom, Inc. | 2 | $31 |
| Exact Sciences | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| GSK | 1 | $19 |
| Merck | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Novartis | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Amgen | 1 | $15 |
| Genentech USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$125
- MOUNJARO$122
- FreeStyle Libre 2$106
How this compares
$2,250 in reported general payments places this provider in the 65th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $15,027 |
| Alendronate Sodium | 14 | $1,593 |
| Gabapentin | 31 | $514 |
| Atorvastatin Calcium | 67 | $483 |
| Metformin Hcl | 67 | $452 |
| Metformin Hcl ErMetformin Hcl | 17 | $368 |
| Fluticasone Propionate | 15 | $339 |
| Amlodipine Besylate | 96 | $335 |
| Metoprolol Succinate | 25 | $291 |
| Losartan Potassium | 48 | $263 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 17 | $258 |
| Levothyroxine Sodium | 18 | $218 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 21 | $208 |
| Simvastatin | 38 | $207 |
| Hydrochlorothiazide | 34 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $105 | $15,02713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 950 medical providers in Georgia.
Other medical in Riverdale
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.